{"product_id":"anti-human-klrg1-monoclonal-antibody-ulviprubart-ua016212","title":"Anti-Human KLRG1 Monoclonal Antibody (Ulviprubart)","description":"\u003ch4\u003eProduct Specification\u003c\/h4\u003e\u003cdiv class=\"responsive-table product-detail-table details-table\"\u003e\n\u003cbr\u003e\u003ctable style=\"width: 100%; height: auto;\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eHost\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003eUlviprubart\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eConcentration\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003e2mg\/mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003eHEK293\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eConjugation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003eUnconjugated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003ePhysical Appearance\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003eLiquid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eStorage Buffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003e\u003cp\u003ePBS pH7.4, containing no preservative\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eStability \u0026amp; Storage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003e\n\u003cp\u003e\u003cspan\u003e2 to 8 °C for 2 weeks under sterile conditions;\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e-20 °C for 3 months under sterile conditions; \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e-80 °C for 24 months under sterile conditions.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePlease avoid repeated freeze-thaw cycles.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eReference\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003e\u003cp\u003e1.Konry T, Sulllivan M, Rozzo A, Ward A, Rao P, Soler-Ferran D, Greenberg S. Single Cell Droplet-Based Efficacy and Transcriptomic Analysis of a Novel Anti-KLRG1 Antibody for Elimination of Autoreactive T Cells. Res Sq [Preprint]. 2024 Sep 8:rs.3.rs-4745216.\u003cbr\u003e2. Brady S, Poulton J, Muller S. Inclusion body myositis: Correcting impaired mitochondrial and lysosomal autophagy as a potential therapeutic strategy. Autoimmun Rev. 2024;23(11):103644.\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\n\u003c\/div\u003e\u003ch4\u003eBackground\u003c\/h4\u003e\u003cdiv\u003e\u003cp\u003e\u003cspan\u003eUlviprubart is a humanized, non-fucosylated monoclonal antibody that targets KLRG1 (killer cell lectin-like receptor G1). Its core mechanism involves specifically binding to and depleting terminally differentiated effector memory T cells (TEM\/TEMRA) that highly express KLRG1, while preserving naïve T cells, regulatory T cells, and B cells, thereby precisely eliminating pathogenic autoreactive T cells. In clinical practice, Ulviprubart is primarily being developed for the treatment of inclusion body myositis (IBM) and T-cell large granular lymphocytic leukemia (T-LGLL). Although the Phase II\/III MUSCLE trial in IBM did not meet its primary endpoint, a trend toward delayed disease progression was observed in the subgroup of patients with mild-to-moderate disease. In T-LGLL, a Phase I study demonstrated a response rate of 53% in those with neutropenia and 22% in those with anemia. The clinical significance of Ulviprubart lies in being the first agent to achieve selective targeting of highly differentiated cytotoxic T cells, offering a novel therapeutic strategy for T-cell-mediated diseases that are refractory to conventional immunosuppression, while further work is needed to identify the optimal patient population who would derive the greatest benefit.\u003c\/span\u003e\u003c\/p\u003e\u003c\/div\u003e","brand":"UA BIOSCIENCE","offers":[{"title":"1mL","offer_id":43033932595275,"sku":"UA016212-1mL","price":615.0,"currency_code":"USD","in_stock":true},{"title":"25μL","offer_id":43033932628043,"sku":"UA016212-25μL","price":70.0,"currency_code":"USD","in_stock":true},{"title":"100μL","offer_id":43033932660811,"sku":"UA016212-100μL","price":140.0,"currency_code":"USD","in_stock":true},{"title":"500μL","offer_id":43033932693579,"sku":"UA016212-500μL","price":410.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0590\/8375\/1499\/files\/16c6b68964134e1687645c319a4ab4b6.jpg?v=1786593626","url":"https:\/\/www.antbioinc.com\/products\/anti-human-klrg1-monoclonal-antibody-ulviprubart-ua016212","provider":"AntBio","version":"1.0","type":"link"}